Last reviewed · How we verify

GTU-multHIV B vaccine and LIPO-5 vaccine

ANRS, Emerging Infectious Diseases · Phase 2 active Biologic

GTU-multHIV B vaccine and LIPO-5 vaccine is a vaccine Biologic drug developed by ANRS, Emerging Infectious Diseases. It is currently in Phase 2 development for Prevention of HIV infection.

The GTU-multHIV B vaccine and LIPO-5 vaccine target multiple HIV epitopes to stimulate both humoral and cellular immune responses.

The GTU-multHIV B vaccine and LIPO-5 vaccine target multiple HIV epitopes to stimulate both humoral and cellular immune responses. Used for Prevention of HIV infection.

At a glance

Generic nameGTU-multHIV B vaccine and LIPO-5 vaccine
SponsorANRS, Emerging Infectious Diseases
Drug classvaccine
TargetMultiple HIV epitopes
ModalityBiologic
Therapeutic areaInfectious Disease
PhasePhase 2

Mechanism of action

These vaccines are designed to present multiple HIV antigens to the immune system, thereby inducing a broad and robust immune response that includes both antibodies and T-cell activation.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GTU-multHIV B vaccine and LIPO-5 vaccine

What is GTU-multHIV B vaccine and LIPO-5 vaccine?

GTU-multHIV B vaccine and LIPO-5 vaccine is a vaccine drug developed by ANRS, Emerging Infectious Diseases, indicated for Prevention of HIV infection.

How does GTU-multHIV B vaccine and LIPO-5 vaccine work?

The GTU-multHIV B vaccine and LIPO-5 vaccine target multiple HIV epitopes to stimulate both humoral and cellular immune responses.

What is GTU-multHIV B vaccine and LIPO-5 vaccine used for?

GTU-multHIV B vaccine and LIPO-5 vaccine is indicated for Prevention of HIV infection.

Who makes GTU-multHIV B vaccine and LIPO-5 vaccine?

GTU-multHIV B vaccine and LIPO-5 vaccine is developed by ANRS, Emerging Infectious Diseases (see full ANRS, Emerging Infectious Diseases pipeline at /company/anrs-emerging-infectious-diseases).

What drug class is GTU-multHIV B vaccine and LIPO-5 vaccine in?

GTU-multHIV B vaccine and LIPO-5 vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is GTU-multHIV B vaccine and LIPO-5 vaccine in?

GTU-multHIV B vaccine and LIPO-5 vaccine is in Phase 2.

What does GTU-multHIV B vaccine and LIPO-5 vaccine target?

GTU-multHIV B vaccine and LIPO-5 vaccine targets Multiple HIV epitopes and is a vaccine.

Related